HomepageNews
2026.05.19
Recently, the Symposium on Healthy China and Biomedical Engineering Innovation and the 5th High-Quality TCM Development Conference were grandly held in Tianjin. At the conference, JumpCan Pharmaceutical was awarded the title of "Thirty-Year Demonstration Unit of TCM Modernization," and its core product, Xiao'er Chiqiao Qingre Granules (Tonpei), was recognized as a "Thirty-Year Demonstration Variety of TCM Modernization," affirming the company's value in TCM inheritance, innovation, and industrial high-quality development. He Yi, Deputy General Manager of JumpCan Pharmaceutical Group and Dean of the TCM Research Institute, was invited to attend the conference and go on stage to receive the award.
The conference was themed "Thirty Years of TCM Modernization." It was hosted by the Medical and Health Department of the Chinese Academy of Engineering, Tianjin University of Traditional Chinese Medicine, the Tianjin Municipal Science and Technology Bureau, and the Tianjin Municipal Health Commission, and organized by the Haihe Laboratory of Modern Chinese Medicine, the State Key Laboratory of Chinese Medicine Modernization, the National Medical Center, National Innovation Center of TCM Modernization, and the Tianjin Association of Integrative Medicine. The conference co-chairs were Academician Zhang Boli, Academician Ji Xunming, and Academician Li Song from the Chinese Academy of Engineering. The conference attracted more than 2,000 representatives from medical, scientific, and industrial sectors, summarizing and sharing the development achievements of TCM modernization over thirty years, jointly deliberating on future TCM development strategies, and discussing innovative initiatives to drive the high-quality development of TCM undertakings and the industry — solidly promoting the integrated development of scientific innovation and industrial innovation, and exerting the academic leadership role of the platform.
Gathering Innovation Strength to Build a Leading Variety Matrix
The conference organizing committee relied on data sources including the Haihe Laboratory of Modern Chinese Medicine, Menet, JD Health, as well as listed company annual reports, and through rigorous selection and prioritization, introduced a batch of "Thirty-Year Demonstration Units of TCM Modernization" to demonstrate and lead the way, aggregate industrial synergies, and jointly drive the vigorous high-quality development of the TCM undertakings. As one of the leading enterprises in the TCM industry, JumpCan Pharmaceutical has always been committed to promoting the modernization and industrialization of TCM.
On the one hand, the company has meticulously cultivated multiple TCM varieties with core competitiveness — including Pudilan Xiaoyan Oral Liquid, Xiao'er Chiqiao Qingre Granules (Tonpei), Jianwei Xiaoshi Oral Liquid, and Huanglong Zhike Granules — focusing on definitive efficacy, appropriate dosage forms, reliable quality, and patient accessibility. The rich and high-quality product matrix provides a solid guarantee for meeting diverse clinical needs.
On the other hand, the company continuously increases scientific research investment, and keeps deepening its efforts in excavation and inheritance of classical formulas, and innovative TCM drug R&D. Currently, the company's TCM new drug marketing applications for Xiao'er Biantong Granules and Chaige Tuire Oral Liquid have both been accepted. Among them, Xiao'er Biantong Granules is expected to be approved for marketing within the year, and become the first Class 1.1 dedicated pediatric TCM drug for pediatric constipation approved following the release of the Clinical R&D Technical Guidelines for New Pediatric TCM Drugs for Constipation (Trial).
JumpCan Pharmaceutical has consistently attracted top R&D talent, actively strengthened exchanges and cooperation with universities, research institutes, and academic institutions, enhanced R&D capabilities for innovative drugs and high-end formulations, built a multi-tiered and diversified product R&D pipeline, and continuously improved its innovation R&D capabilities. The company was awarded the Second Prize of the National Science and Technology Progress Award in 2021 and 2024, respectively.
Inheriting and Developing Renowned Physician Prescriptions, Improving Children's Drug Experience
Xiao'er Chiqiao Qingre Granules (Tonpei) originates from the classic prescription formulated by Li Shaochuan, one of China's first batch of veteran renowned TCM practitioners, drawing on over fifty years of medical practice. With rigorous compatibility, definitive efficacy, and wide clinical application, it has been included in national diagnosis and treatment plans and related guidelines and consensus multiple times. With its excellent clinical performance, it has become one of the commonly stocked Chinese patent medicines for children in families, receiving widespread recognition from the industry and parents.
On the clinical application side, to continuously improve pediatric medication compliance and experience, the company has introduced a new formulation — Xiao'er Chiqiao Qingre Syrup (K-tonpei) — based on the original granule formulation. This product is also the first improved new TCM drug approved under the Provisions for Drug Registration, further enriching children's drug options and facilitating pediatric medication.
Being selected as a Demonstration Unit and Demonstration Variety represents high recognition of JumpCan Pharmaceutical's thirty years of practice in TCM modernization. In the future, the company will continue to uphold the original intention of TCM, deepen inheritance and innovation, strengthen new drug R&D and achievement transformation, continuously improve product quality and clinical value, and contribute industrial strength to promoting high-quality TCM development and building a Healthy China.